Traduction de «Drug product » (Anglais → Français) :

drug | drug product | medicinal product | medicine | pharmaceutical | pharmaceutical product

medicinal product not subject to medical prescription | non-prescription drug | non-prescription medicinal product | OTC drug | OTC medicine | over-the-counter drug | over-the-counter medicine

over-the-counter drug [ non-prescription drug | non-prescription medicinal product | OTC drug | OTC medicine | over-the-counter medicine ]

ethical drug | medicinal product subject to medical prescription | prescription drug | prescription medicine | prescription only medicine | prescription-only medicinal product | Rx drug | POM [Abbr.]

developing therapeutic products | pharmaceutical drug developing | develop pharmaceutical drugs | therapeutic products developing

Therapeutic Products Directorate [ TPD | Therapeutic Products Programme | Drugs and Medical Devices Directorate | Drugs and Medical Devices Programme | Drugs Directorate ]

drug surveillance [ pharmaceutical surveillance | supervision of medicinal products | supervision of pharmaceutical drugs ]

drug addiction [ drug abuse | drug-taking | fight against drugs | drug addicts(UNBIS) ]

conducting of drug and alcohol abuse tests | drug abuse tests conduct | conduct drug abuse tests | conducting of drug abuse tests

execute workplace drug policies | prohibit drug and alcohol use in the workplace | enforce workplace drug policies | implement workplace drug policies

“scheduled substance” means any substance listed in Annex I that can be used for the illicit manufacture of narcotic drugs or psychotropic substances, including mixtures and natural products containing such substances but excluding mixtures and natural products which contain scheduled substances and which are compounded in such a way that the scheduled substances cannot be easily used or extracted by readily applicable or economically viable means, medicinal products as defined in point 2 of Article 1 of Directive 2001/83/EC of the Eu ...[+++]ropean Parliament and of the Council (9) and veterinary medicinal products as defined in point 2 of Article 1 of Directive 2001/82/EC of the European Parliament and of the Council (10);

Question No. 609 Ms. Anne Minh-Thu Quach: With respect to drug regulation and approval: (a) does the 2012 Economic Action Plan provide for decreases or increases in the financial and human resources allocated to (i) drug approval services, (ii) regulatory activities to evaluate and monitor the safety, efficacy and quality of drugs before and after they enter the marketplace, (iii) activities related to the review of submissions by drug manufacturers for market authorization and post-market changes, (iv) activities related to enforcing compliance with existing regulations, including those concerning clinical trials, drug manufacturing and the reporting of adverse drug reactions, (v) activities of the Patented Medicine Prices Review Board, (v ...[+++]i) services such as the Patent Register, Drug Product Database, Notice of Compliance, and Progressive Licensing Project, (vii) various areas of Health Canada such as the Marketed Health Products Directorate, Therapeutic Products Directorate, Biologics and Genetic Therapies Directorate, and the Veterinary Drugs Directorate; (b) for each of the programs and directorates listed in (a), (i) what is the estimated extent of the decreases or increases in human or financial resources, (ii) are positions expected to be cut and, if so, how many will be eliminated; (c) was a value-for-money assessment conducted for the drug approval process; and (d) what is the government’s financial allocation plan regarding drug regulation?

(Return tabled) Question No. 530 Ms. Anne Minh-Thu Quach: With regard to Health Canada and the drug shortage: (a) what are the various plans that have been brought forward since 1990 to address drug shortages; (b) based on which studies is the Minister promoting a voluntary reporting mechanism for the industry to address drug shortages; (c) what are Health Canada’s budgets for inspecting drug manufacturing plants; (d) does Health Canada have a budget for identifying new emergency suppliers in case of a shortage; (e) what are Health Canada’s preferred contingency plans in the event of a sudden production shutdown, such as a bankruptcy ...[+++] or a plant fire; (f) since a few producers are the only ones to produce a given drug, what recourse does Health Canada have if a sudden production shutdown affects a sole producer of a drug; (g) what are the fast-track mechanisms for identifying alternatives for drugs in short supply; (h) in the event of a shortage, how does Health Canada prioritize its shipments of stockpiled products; (i) if there is no surplus inventory and if there is no alternate manufacturer, how does Health Canada determine who has the greatest need for the drugs; (j) what solutions based on what is done in other countries around the world have been considered by Health Canada; and (k) has Health Canada considered a solution based on the Swedish model, where a state-owned corporation produces about 2 percent of the country’s demand for drugs?

In the field of drug supply reduction, the objective of the EU Drugs Strategy 2013-20 is to contribute to a measurable reduction of the availability of illicit drugs, through the disruption of illicit drug trafficking, the dismantling of organised crime groups that are involved in drug production and trafficking, efficient use of the criminal justice system, effective intelligence-led law enforcement and increased intelligence sharing.